LLY

922.39

-1.51%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

TMO

572.75

+1.15%↑

Search

Johnson and Johnson

Fermé

SecteurSoins de santé

186.29 -0.03

Résumé

Variation du prix de l'action

24h

Actuel

Min

185.66

Max

188.22

Chiffres clés

By Trading Economics

Revenu

-385M

5.2B

Ventes

250M

24B

P/E

Moyenne du Secteur

17.979

77.256

BPA

2.8

Rendement du dividende

2.69

Marge bénéficiaire

21.473

Employés

138,100

EBITDA

546M

9.3B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.43% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.69%

2.33%

Date du Prochain Dividende

9 déc. 2025

Date du Prochain Détachement de Dividende

25 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-11B

449B

Ouverture précédente

186.32

Clôture précédente

186.29

Sentiment de l'Actualité

By Acuity

26%

74%

65 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Johnson and Johnson Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 oct. 2025, 10:35 UTC

Résultats

J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains

5 nov. 2025, 19:38 UTC

Résultats

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

5 nov. 2025, 17:00 UTC

Résultats

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

3 nov. 2025, 16:15 UTC

Acquisitions, Fusions, Rachats

Kimberly-Clark Stock Heads for Biggest One-Day Drop Since Black Monday -- WSJ

31 oct. 2025, 12:20 UTC

Résultats

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings. -- Barrons.com

30 oct. 2025, 11:32 UTC

Résultats

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

14 oct. 2025, 10:51 UTC

Market Talk
Résultats

J&J Sales Get Boost From Tremfya Drug -- Market Talk

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson Raises 2025 View To Sales $93.5B-$93.9B Vs Prior View $93.2B-$93.6B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson Now Sees 2025 Operational Sales of $93B-$93.4B Vs Prior Range $92.7B-$93.1B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.5%-4% Vs Prior Outlook 3.2%-3.7% >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson Backs 2025 Adj EPS $10.80-Adj EPS $10.90 >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson: 3Q MedTech Business Delivered Operational Sales Grew 5.6%, Driven Primarily by Electrophysiology Products, Abiomed, Shockwave, Wound Closure Pdts and Surgical Vision >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Grew 5.3%, With Net Acquisitions and Divestitures Positively Affecting Growth by 1.6% Due to Caplyta >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson Still Sees 2025 Adjusted Operational EPS $10.63-$10.73 >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.8%-5.3% Vs Prior Range 4.5%-5% >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya, Simponi/Simponi Aria and Spravato >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Adj EPS $2.80 >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Sales $23.99B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q EPS $2.12 >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q EPS $2.12 >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14 oct. 2025, 10:20 UTC

Résultats

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

Comparaison

Variation de prix

Johnson and Johnson prévision

Objectif de Prix

By TipRanks

10.43% hausse

Prévisions sur 12 Mois

Moyen 206.47 USD  10.43%

Haut 225 USD

Bas 176 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

19 ratings

12

Achat

7

Maintien

0

Vente

Score Technique

By Trading Central

154.93 / 155.895Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

65 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat